Coya Therapeutics (COYA) Stock Price, News & Analysis

Company Overview

Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors. The company employs a proprietary screening platform to identify and optimize compounds that selectively bind or inhibit UNC-45A in diseased tissues, while minimizing off-target effects in healthy cells. In addition to its internal research, Coya has established collaborations with academic and industry partners to accelerate translational studies and position its candidates for clinical entry.

Headquartered in Boston, Massachusetts, Coya Therapeutics leverages a multidisciplinary team of scientists with expertise in molecular biology, medicinal chemistry and translational medicine. The company is committed to advancing its pipeline through proof‐of‐concept studies, with the goal of delivering novel therapies that improve outcomes for patients suffering from high‐unmet‐need fibrotic and oncologic indications. Coya’s strategic focus on mechanistic innovation seeks to create durable treatment options where current standards of care are limited.

Key Stats

• Today's Range: $4.52 to $4.85
• 50-Day Range: $3.87 to $6.07
• 52-Week Range: $3.71 to $7.75
• Volume: 130,175 shs
• Average Volume: 207,352 shs
• Market Capitalization: $112.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.33
• Consensus Rating: Moderate Buy

Coya Therapeutics Stock Analysis - MarketRank™

Coya Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 627th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Coya Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Coya Therapeutics has a consensus price target of $15.33, representing about 219.4% upside from its current price of $4.80.

Amount of Analyst Coverage

Coya Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Coya Therapeutics are expected to decrease in the coming year, from ($1.49) to ($1.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Coya Therapeutics is -4.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Coya Therapeutics is -4.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Coya Therapeutics has a P/B Ratio of 2.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.87% of the float of Coya Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Coya Therapeutics has a short interest ratio ("days to cover") of 5.18.

Change versus previous month

Short interest in Coya Therapeutics has recently increased by 2.33%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Coya Therapeutics does not currently pay a dividend.

Dividend Growth

Coya Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 8 news articles for Coya Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for COYA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Coya Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Coya Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.10% of the stock of Coya Therapeutics is held by insiders.

Percentage Held by Institutions

39.75% of the stock of Coya Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:COYA
• CIK: 1835022
• Web: www.coyatherapeutics.com
• Phone: 800-587-8170
• Fax: N/A
• Employees: 6
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Coya Therapeutics: $15.33
• High Price Target: $18.00
• Low Price Target: $12.00
• Potential Upside/Downside: +219.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.23 million
• Net Margins: -266.10%
• Pretax Margin: -266.07%
• Return on Equity: -55.86%
• Return on Assets: -48.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.02
• Quick Ratio: 15.02

Sales & Book Value

• Annual Sales: $7.95 million
• Price / Sales: 14.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.06 per share
• Price / Book: 2.33

Miscellaneous

• Outstanding Shares: 23,460,000
• Free Float: 22,026,000
• Market Cap: $112.61 million
• Optionable: Not Optionable
• Beta: 0.60